{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-066306","form_type":"8-K","ticker":null,"cik":"0001711933","company_name":"Akoya Biosciences, Inc.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.748750+00:00","generated_at":"2026-05-18T09:06:55.815097+00:00","sec_items":["1.02","2.01","3.01","3.03","5.03","5.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Akoya Biosciences completes merger with Quanterix; shareholders receive 0.1461 QTRX shares + $0.38 cash per share","bullets":["Merger closed July 8, 2025; Akoya is now a wholly owned subsidiary of Quanterix (QTRX).","Per share: 0.1461 Quanterix shares plus $0.38 cash; adjustments ensure no more than 19.99% of QTRX shares or $20M cash issued.","All outstanding Akoya RSUs and options converted or cancelled per merger agreement.","Board and executive officers replaced with Quanterix appointees; Akoya common stock delisted from Nasdaq.","Prior credit agreement, ESPP, and equity distribution agreement terminated in connection with merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-066306","json":"https://secwatch.observer/filing/0001104659-25-066306.json","markdown":"https://secwatch.observer/filing/0001104659-25-066306.md","text":"https://secwatch.observer/filing/0001104659-25-066306.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711933/000110465925066306/0001104659-25-066306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711933/000110465925066306/tm2520065d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:06:55.815097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70d1cfc0644dba0aa82b5f95ef1cc9c782538c43","claim":"Akoya Biosciences, Inc.: The bylaws were amended and restated to become the bylaws of the surviving Merger Sub.","evidence_excerpt":"at the Effective Time, the bylaws of Merger Sub as in effect as of immediately prior to the Effective Time became the Amended and Restated Bylaws of Akoya","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711933/000110465925066306/0001104659-25-066306-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"caae1b90432a430b235f00dff02d3a6eb98df7ff","claim":"Akoya Biosciences, Inc.: The Certificate of Incorporation was amended and restated pursuant to the Merger Agreement.","evidence_excerpt":"at the Effective Time, the Certificate of Incorporation of Akoya was amended and restated in the form of the Amended and Restated Certificate of Incorporation that is filed as Exhibit 3.1 hereto","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711933/000110465925066306/0001104659-25-066306-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}